VYNE Therapeutics (VYNE) AI Stock Analysis

• Market Cap: $8.51M
• Dividend Yield: N/A
• Average Volume (3M): 3.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.15
• Revenue Growth: -2.06%
• EPS Growth: 64.86%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 25,472,164
• 10 Day Avg. Volume: 1,802,469
• 30 Day Avg. Volume: 3,100,251
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 3.64
• Enterprise Value/Revenue: 64.98
• Enterprise Value/Gross Profit: 64.98
• Enterprise Value/Ebitda: -0.73
• 1Y Price Target: $1.25
• Price Target Upside: 278.79% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5

• Rating: 40 Underperform
• Price Target: $0.50 ▲(51.52% Upside)

VYNE Therapeutics faces significant challenges, with financial instability, negative technical indicators, and a recent setback in its clinical trials. These factors contribute to a low stock score, underscoring the risks associated with investing in VYNE at this time.

Positive Factors

Preclinical Data

VYN202 has demonstrated promising preclinical data across multiple models of fibro-inflammatory disease and hematologic malignancies.

Regulatory Approval

The FDA lifted the clinical hold on 0.25 and 0.5mg doses of VYN202 for female patients, offering encouraging proof-of-concept for VYN202 and highlighting its potential across various autoimmune indications.

Negative Factors

Clinical Trial Discontinuation

VYNE will discontinue treatment in the ongoing extension phase and terminate the trial due to repibresib not meeting primary endpoint or key secondary endpoint.

Clinical Trial Results

The Phase IIb study evaluating repibresib gel in nonsegmental vitiligo did not meet its primary or key secondary endpoint.

Investor Sentiment

Short interest in the stock is relatively high, indicating a significant level of skepticism among investors.

VYNE Therapeutics Business Overview & Revenue Model

Company Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

How the Company Makes Money

VYNE Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company's revenue model includes potential product sales upon successful approval of its drug candidates, licensing agreements with larger pharmaceutical companies, and government or private grants aimed at supporting research and development initiatives. Additionally, VYNE may enter into partnerships with other biotechnology firms or pharmaceutical companies that can provide upfront payments, milestone payments based on developmental progress, and royalties on future sales. The success of these collaborations and the completion of clinical trials are critical factors that contribute to the company's earnings.

VYNE Therapeutics Financial Statement Overview

Summary

VYNE Therapeutics is struggling financially with significant declines in revenue, negative profit margins, and ongoing cash burn. Despite a strong equity position, the company's inability to achieve profitability and generate positive cash flow is concerning.

Income Statement

VYNE Therapeutics has shown a significant decline in revenue over recent years, with a steep drop from 2020 to 2024. The gross profit margin is positive, but the company is facing substantial operating losses as evidenced by negative EBIT and EBITDA margins. The net profit margin is also significantly negative, highlighting persistent unprofitability. These metrics indicate challenges in achieving revenue growth and controlling costs.

Balance Sheet

The company has maintained a healthy equity position with a low debt-to-equity ratio, suggesting limited leverage risk. However, there is a consistent decrease in stockholders' equity over the last few years. The equity ratio is relatively strong, indicating a stable asset base primarily funded by equity. Despite these strengths, profitability remains an issue.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash burn, which is a concern for sustainability. Free cash flow has been negative, with limited growth in free cash flow, suggesting cash management challenges. The company has relied on financing activities to supplement cash needs, which could pose future risks if access to capital markets becomes constrained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	476.00K	501.00K	424.00K	477.00K	14.76M	20.99M
Gross Profit	476.00K	501.00K	424.00K	477.00K	11.41M	19.60M
EBITDA	-42.59M	-43.63M	-29.26M	-34.22M	-38.94M	-251.09M
Net Income	-38.55M	-39.83M	-28.45M	-33.95M	-73.33M	-255.57M
Balance Sheet
Total Assets	44.72M	66.91M	97.69M	40.76M	67.05M	93.74M
Cash, Cash Equivalents and Short-Term Investments	39.65M	61.52M	93.25M	30.91M	42.25M	58.59M
Total Debt	25.00K	99.00K	214.00K	-349.00K	349.00K	34.78M
Total Liabilities	5.84M	14.82M	8.95M	9.56M	18.41M	56.25M
Stockholders Equity	38.88M	52.09M	88.73M	31.20M	48.64M	37.49M
Cash Flow
Free Cash Flow	-39.89M	-34.09M	-25.34M	-29.20M	-56.37M	-137.19M
Operating Cash Flow	-39.77M	-33.97M	-25.34M	-29.20M	-56.37M	-137.08M
Investing Cash Flow	32.42M	23.36M	-57.35M	15.67M	1.03M	89.11M
Financing Cash Flow	-255.00K	-141.00K	82.39M	1.65M	39.78M	61.81M

VYNE Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Negative. The current price of 0.33 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.94, and below the 200-day MA of 1.88, indicating a bearish trend. The MACD of -0.20 indicates Negative momentum. The RSI at 29.44 is Positive, neither overbought nor oversold. The STOCH value of 9.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYNE.

VYNE Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLNN	54 Neutral	$56.55M	―	-1738.36%	―	-35.29%	45.18%
Sector *	51 Neutral	$7.89B	-0.12	-39.89%	2.16%	21.38%	-1.56%
PLUR	49 Neutral	$44.49M	―	-1205.58%	―	203.23%	13.57%
DARE	46 Neutral	$28.58M	―	597.53%	―	88.13%	92.45%
PYPD	41 Neutral	$35.67M	―	-312.77%	―	―	61.18%
VYNE	40 Underperform	$8.51M	―	-67.73%	―	-2.06%	64.86%
NRSN	30 Underperform	$28.86M	―	-2880.11%	―	―	31.09%

VYNE Therapeutics Corporate Events

VYNE Therapeutics Directors Resign Amid Financial Updates

On August 11 and 13, 2025, Christine Borowski and Anthony Bruno resigned from VYNE Therapeutics‘ board, with no disputes involved. VYNE reported its second quarter 2025 financial results, highlighting a promising efficacy signal from its VYN202 program in a Phase 1b trial for plaque psoriasis. Despite a clinical hold due to testicular toxicity in dogs, the FDA lifted the hold for female subjects, and VYNE plans further studies. The company also reported mixed results from its Phase 2b trial of repibresib gel for vitiligo, leading to the trial’s termination. Financially, VYNE reduced costs, extending its cash runway into 2027, and reported a decreased net loss compared to the previous year.

VYNE Therapeutics Ends Phase 2b Trial for Repibresib

On July 30, 2025, VYNE Therapeutics announced the topline results of its Phase 2b trial evaluating Repibresib gel in nonsegmental vitiligo. The trial, which involved 177 subjects, did not meet its primary or key secondary endpoints, leading the company to terminate the trial’s extension phase and seek external partners for further development. Despite the setbacks, VYNE observed nominally statistically significant effects in certain secondary and exploratory endpoints and remains committed to its InhiBET™ BET inhibitor platform. The company also reported an estimated $39.6 million in cash and investments as of June 30, 2025, though these figures are preliminary and unaudited.